Dupont J, Orgiazzi J, Burger A
Service de Médecine Interne-Endocrinologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite.
Rev Med Interne. 1993 Feb;14(2):93-9. doi: 10.1016/s0248-8663(05)81258-5.
We report a case of thyrotoxicosis in a male patient under alpha-interferon (INF-alpha) therapy. Data from the literature show that treatment with IFN-a alone or combined with interleukin-2 (IL-2) can induce dysthyroidism (hypothyroidism, hyperthyroidism, thyroiditis). The frequency of dysthyroidism under INF-alpha therapy ranges from 10 to 40% depending on the authors. During combined INF-alpha and IL-2 therapy these figures reach 20 to 91%. The presence of anthyroid antibodies before treatment makes it more probable that dysthyroidism will occur. The administration of INF-alpha can exacerbate or induce various autoimmune diseases.
我们报告一例接受α-干扰素（INF-α）治疗的男性患者发生甲状腺毒症的病例。文献数据表明，单独使用IFN-α或与白细胞介素-2（IL-2）联合使用均可诱发甲状腺功能障碍（甲状腺功能减退、甲状腺功能亢进、甲状腺炎）。根据不同作者的研究，INF-α治疗下甲状腺功能障碍的发生率在10%至40%之间。在INF-α与IL-2联合治疗期间，这些数字可达20%至91%。治疗前存在抗甲状腺抗体使发生甲状腺功能障碍的可能性更大。INF-α的使用可加重或诱发各种自身免疫性疾病。
